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Abstract
Apoptotic priming controls the commitment of cells to apoptosis by determining how close they lie to mitochondrial
permeabilisation. Variations in priming are important for how both healthy and cancer cells respond to
chemotherapeutic agents, but how it is dynamically coordinated by Bcl-2 proteins remains unclear. The Bcl-2 family
protein Bid is phosphorylated when cells enter mitosis, increasing apoptotic priming and sensitivity to antimitotic
drugs. Here, we report an unbiased proximity biotinylation (BioID) screen to identify regulators of apoptotic priming in
mitosis, using Bid as bait. The screen primarily identified proteins outside of the canonical Bid interactome. Specifically,
we found that voltage-dependent anion-selective channel protein 2 (VDAC2) was required for Bid phosphorylation-
dependent changes in apoptotic priming during mitosis. These results highlight the importance of the wider Bcl-2
family interactome in regulating the temporal control of apoptotic priming.
Introduction
Cells respond to an apoptotic stimulus via mitochon-
drial outer-membrane permeabilisation (MOMP), releas-
ing pro-apoptotic factors into the cytosol1. However, the
proportion of cells that undergo MOMP varies both
within and between different cell types2–4. Apoptotic
priming refers to how close a cell lies to MOMP5,6.
Primed cells readily undergo MOMP following a pro-
apoptotic signal, whereas unprimed cells tolerate a greater
level of damage. Apoptotic priming of cancer cells can
predict the response to chemotherapy7,8, and changes
dynamically as cells respond to damage signals. How these
changes are coordinated is poorly understood6,9.
MOMP is controlled by Bcl-2 family proteins, com-
prising pro-apoptotic Bax and Bak, which form the pores
that drive MOMP, anti-apoptotic proteins, like Bcl-XL,
Bcl-2 and Mcl-1, that suppress MOMP by sequestering
pro-apoptotic proteins and BH3-only proteins, which
regulate the activity of the other two groups10,11. BH3-
only proteins may be activators or sensitisers. Activators,
like Bim and Bid, bind Bax and Bak to initiate MOMP.
These activators can be sequestered by anti-apoptotic Bcl-
2 proteins, but then released by sensitisers, such as Bad12.
Thus, variation in the expression and interaction land-
scape of the Bcl-2 family sets the threshold for MOMP,
with changes in this balance having profound
consequences13.
Cells become primed during mitosis, with those failing
to divide being eliminated9. Priming is reduced once cells
satisfy the spindle-assembly checkpoint (SAC) and enter
anaphase. Drugs like Taxol exploit this by preventing
transition to anaphase, but a gradual degradation of cyclin
B1 can allow cancer cells to exit mitosis without satisfying
the SAC, termed mitotic slippage14. Mitosis has been
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linked to post-translational modification of several Bcl-2
proteins15–20, changes in their expression21,22 and degra-
dation16,23. We previously demonstrated that Bid, an
activator BH3-only protein, becomes phosphorylated in
mitosis, which increased apoptotic priming independent
of its canonical regulation via caspase-8 proteolysis20.
Together, these events set the mitotic Bcl-2 landscape and
therefore determine how long a cell resists apoptosis
whilst attempting to satisfy the SAC. Thus, mitosis pro-
vides an opportunity for understanding how cells dyna-
mically adjust priming within precise temporal
boundaries.
To identify how cells coordinate temporal changes in
priming during mitosis, we performed an unbiased pro-
teomic screen using proximity-dependent biotin identifi-
cation (BioID)24. As we previously identified that Bid
phosphorylation regulates priming in mitotic cells, we
used full-length (FL) Bid as bait. We identify that the
predominant proteins identified in live cells are outside
the canonical Bid interactome and the Bcl-2 protein
family. In particular, we identify that the outer mito-
chondrial porin, voltage-dependent anion channel 2
(VDAC2), is required for cells to temporally increase
apoptotic priming following mitotic Bid phosphorylation.
Results
Using BioID to interrogate the Bid interactome in live cells
In order to interrogate temporal regulation of priming,
we examined post-translational modifications (PTMs)
known to alter Bcl-2 protein function in mitosis. Focusing
on mitosis is useful for a proteomic screen targeting
temporal changes in priming, as cells are readily enriched
in the M phase. Bid becomes phosphorylated in mitosis
(serine 66 in mouse, 67 in human; mBid and hBid,
respectively)20, which increased priming in colon carci-
noma cells and their sensitivity to apoptosis during Taxol-
induced mitotic arrest. We decided to exploit this tem-
poral regulation of Bid phosphorylation to identify
mitosis-specific regulators of priming.
To identify regulators of Bid function, we employed
biotin-labelling identification (BioID), a powerful
approach for interrogating protein complexes in live
cells24–27. In this approach, a bait protein is expressed as a
fusion with the E. coli biotin ligase BirA containing a
R118G substitution, along with a myc epitope (BirA*). On
addition of excess biotin to the culture media, BirA*
generates reactive biotinyl-5′-AMP that can covalently
bond to primary amines. The half-life of reactive biotinyl-
5′-AMP limits the effective labelling radius to ~20 nm24.
Consequently, if BirA* is expressed fused to a bait protein,
there will be enrichment for biotinylated proteins prox-
imal to that bait, which can be isolated by streptavidin-
affinity purification (Fig. 1A). As labelling occurs in situ,
BioID is particularly useful for interrogating complexes
unsuited to detergent extraction, a known issue for Bcl-2
proteins28,29. We therefore generated mBid–BirA* baits to
identify interacting partners in live cells.
To validate mBid–BirA* fusions, we compared the pro-
apoptotic function of truncated Bid (tBid) fused to either
eYFP or BirA*. Both induced similar levels of apoptosis
when transiently expressed in HEK-293T cells (Supple-
mentary Fig. S1A). A venus-BirA* fusion did not induce
apoptosis. We next validated tBid–BirA*-dependent bio-
tin labelling. Due to its potent pro-apoptotic activity, cells
stably expressing tBid–BirA* could not be generated.
Therefore, HEK-293T cells transiently expressing either
tBid–BirA* or BirA* were grown in media with or without
supplementary biotin for 18 h. Whole-cell lysates (WCL)
were probed with streptavidin (to detect biotinylated
proteins) or anti-myc (Supplementary Fig. S1B). Both
BirA*-fusion proteins showed self-labelling in the pre-
sence of biotin, although due to the pro-apoptotic activity
of tBid–BirA* (Supplementary Fig S1A), labelling
appeared weaker than with control BirA*. As expected,
levels of the four endogenously biotinylated carboxylases
in mammalian cells were unaffected by BirA* or
tBid–BirA* expression30. To determine if tBid–BirA*
could biotinylate known binding partners, we transiently
expressed GFP-Bcl-XL in HEK-293T cells, alone or with
tBid–BirA*. Transfected cells were supplemented with
biotin; WCL was subjected to streptavidin-affinity pur-
ification and blotted for GFP and biotin (using anti-GFP
and streptavidin, respectively) (Supplementary Fig. S1C).
GFP-Bcl-XL bound streptavidin beads only when co-
expressed with tBid–BirA*, confirming that BioID cap-
tured interactions between tBid and anti-apoptotic Bcl-2
proteins in situ. Finally, we visualised biotin in cells
expressing tBid–BirA* or BirA* using immuno-
fluorescence microscopy (Supplementary Fig. S1D). Only
cells expressing either tBid–BirA* or BirA* were positive
for biotin. In tBid–BirA*-expressing cells, both the anti-
myc and biotin labelling appeared punctate.
To identify mitosis-specific interactions, we used
quantitative, label-free mass spectrometry with HeLa cells
stably expressing BirA* bait proteins, which allowed
robust mitotic enrichment. We generated stable HeLa
lines expressing mBidWT–BirA* or venus BirA*, as well
as Bid variants that were either not phosphorylated in
mitosis (mBidS66A–BirA*), or where the BH3 domain
required for interacting with other Bcl-2 proteins was
non-functional (mBidG94E–BirA*). Fusion proteins were
expressed from a lentivirus co-expressing tagBFP down-
stream of a T2A-cleavage sequence, allowing FACS
selection of cells with similar expression levels of each bait
and control (Fig. 1B). Cells were maintained in biotin-
supplemented media, containing either nocodazole or
DMSO (unsynchronised), for 16 h, which allowed
enrichment for labelling in mitosis vs. interphase (Fig.
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1C). Labelled proteins were isolated by streptavidin-
affinity purification (AP), analysed by LC–MS/MS and
abundance quantified using Progenesis QI. Three inde-
pendent experiments typically identified >400 proteins
within each sample (Fig. 1D). Quantification of enrich-
ment for individual proteins was determined by compar-
ing their relative abundance in each mBid–BirA* sample
to the experimentally paired venus-BirA* control. To
Fig. 1 BioID workflow for identification of Bid vicinal proteins in mitotic cells. A Schematic diagram of BioID labelling strategy. Selective
biotinylation of proximal proteins is followed by stringent cell lysis for streptavidin-affinity purification and identification/quantification by LC–MS/MS.
B HeLa cells, either wild type or stably expressing mBidWT–BirA*, mBidS66A–BirA*, mBidG94E–BirA* or venus BirA*, were grown with 50 µM biotin for
16 h in the presence (+) or absence (−) of nocodazole. Whole-cell lysates were prepared and examined by immunoblotting for the indicated
antibodies and streptavidin. C Single-cell-fate profiles of HeLa cells in the presence or absence of nocodazole, imaged over 48 h. Each individual
horizontal line represents a single cell. Data represent 90 cells tracked over three independent repeats. A biotin-labelling window of 16 h significantly
enriched for mitotic cells compared to untreated controls, without significant enrichment for apoptotic cells. D Volcano plot of mean- fold change of
biotinylated protein abundance for mBidWT–BirA* vs. venus-BirA* control for unsynchronised and nocodazole-treated samples. Positive ratio
indicates enrichment in BidWT sample. P value calculated via ANOVA from three independent replicates.
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prioritise proteins for further analysis, selection was
restricted to those enriched in mBidWT–BirA* cells in all
three experimental repeats (Fig. 2A and Tables 1 and 2).
Surprisingly, proteins enriched in both unsynchronised
and mitotic mBid–BirA* cells were not associated with
Bid’s documented roles within intrinsic or extrinsic
apoptotic pathways. The STRING database31,32 predicted
that the top ten most enriched partners of Bid would be
other Bcl-2 proteins, components of the death-induced
signalling complex (DISC) and caspases (Fig. 2B). How-
ever, proteins enriched by mBid–BirA* did not overlap
with this predicted network. We considered that one
possibility for this apparent lack of canonical partners
might be that these interactions had largely been defined
with caspase-cleaved or tBid, and may not represent the
main interacting proteins for FL-Bid used in this assay.
Fig. 2 FL-Bid-based BioID mass-spectrometry screen does not enrich canonical Bcl-2 family proteins. A Venn diagram showing proteins
identified as enriched by mBidWT–BirA* vs. venus BirA* under unsynchronised and nocodazole-treated conditions. Only proteins identified as
enriched in all three independent experiments are shown. Proteins identified in both conditions are shaded grey. B The predicted protein-interaction
network for Bid, derived from the top ten highest-scoring predicted interaction partners as described by STRING. STRING score derived from
experimentally validated interactions and interactions in curated databases only. Nodes in blue represent death receptors/death-receptor ligands,
nodes in brown represent caspases, while nodes in green represent Bcl-2 proteins. C Bcl-2 family proteins are identified in the mBid–BirA* data set
when the stringency is lowered. In total, 32 proteins, including voltage-dependent anion channel 2 (VDAC2), were identified as being enriched in
mBid–BirA* vs. venus BirA* in three out of three replicates (blue inner circle). Bax was enriched in two out of three replicates. Bcl-XL (BCL2L1) was
enriched in one out of three replicates.
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Table 1 Summary of enrichment data in unsynchronised HeLa cells, from three independent experiments (R1, R2 and
R3) comparing mBidWT–BirA* relative to venus BirA*.
Gene name Description/protein name CRAPome % Sequence
coverage
Log2 (ratio)
R1 R2 R3 Mean
BID BH3-interacting domain death agonist 1.46 N/A 3.094 3.709 5.261 4.021
DDX3X ATP-dependent RNA helicase DDX3X 51.58 25.0% 0.595 1.327 1.894 1.272
HNRNPDL Heterogeneous nuclear ribonucleoprotein D-like 33.82 6.3% 0.362 0.411 2.660 1.144
EIF4G1 Eukaryotic translation-initiation factor 4 gamma 1 24.82 14.0% 2.489 0.249 0.646 1.128
FLNC Filamin C 35.77 4.4% 0.016 0.541 2.190 0.916
EIF4A1 Eukaryotic initiation factor 4A-I 46.23 45.0% 0.262 1.085 1.327 0.891
CAND1 Cullin-associated NEDD8-dissociated protein 1 21.41 6.3% 0.157 1.904 0.550 0.870
XRN2 5′–3′ exoribonuclease 2 23.60 2.9% 0.568 0.379 1.413 0.787
SEPT9 Septin 9 19.22 35.0% 0.309 1.482 0.448 0.746
SLC25A11 Mitochondrial 2-oxoglutarate/malate carrier protein (fragment) 13.38 8.8% 0.073 0.757 1.389 0.739
SON Protein SON 17.27 0.7% 0.069 0.382 1.564 0.672
RPA1 Replication protein A 70-kDa DNA-binding subunit 20.44 8.6% 0.233 0.440 1.328 0.667
RPN1 Dolichyl-diphosphooligosaccharide–protein glycosyltransferase
subunit 1
22.14 18.0% 1.114 0.428 0.374 0.639
DSP Desmoplakin 30.66 17.0% 0.508 0.772 0.537 0.606
NAT10 RNA cytidine acetyltransferase 17.03 4.5% 0.091 0.640 1.053 0.595
VDAC2 Voltage-dependent anion channel 2 14.11 49.0% 0.193 1.361 0.143 0.566
HUWE1 HECT, UBA and WWE domain-containing 1 18.00 0.3% 0.349 0.087 1.176 0.537
RBBP6 E3 ubiquitin–protein ligase RBBP6 9.49 1.9% 0.583 0.313 0.686 0.527
H2AFY Histone H2A 16.55 5.9% 0.770 0.304 0.378 0.484
SFPQ Splicing factor, proline- and glutamine-rich 48.91 7.2% 0.070 0.642 0.659 0.457
DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 31.87 3.1% 0.081 0.388 0.873 0.447
RPL23A 60s ribosomal protein L23a (fragment) 54.50 20.0% 0.091 0.608 0.596 0.432
MAP4 Microtubule-associated protein 20.44 11.0% 0.345 0.767 0.165 0.426
STAT1 Signal transducer and activator of transcription 1-alpha/beta 5.60 12.0% 0.056 0.231 0.825 0.371
HSPA9 Stress-70 protein, mitochondrial (fragment) 74.70 25.0% 0.774 0.060 0.196 0.343
PCBP2 Poly(rC)-binding protein 2 (fragment) 45.99 26.0% 0.125 0.737 0.059 0.307
DLST Dihydrolipoamide S succinyltransferase (E2 component of 2-oxo-
glutarate complex)
13.87 4.4% 0.150 0.205 0.532 0.296
ABCD3 ATP-binding cassette subfamily D member 3 9.73 3.5% 0.003 0.281 0.567 0.284
DKFZp686L20222 Putative uncharacterised protein DKFZp686L20222 19.71 26.0% 0.265 0.289 0.291 0.282
CORO1B Coronin 9.25 38.0% 0.011 0.416 0.336 0.254
DNA helicase DNA helicase N/A 11.0% 0.274 0.217 0.047 0.179
PAICS Multifunctional protein ADE2 25.79 40.0% 0.101 0.121 0.268 0.164
PRDX1 Peroxiredoxin 1 61.56 45.0% 0.057 0.019 0.292 0.122
CSDE1 Cold-shock domain-containing E1, RNA-binding isoform 16.30 21.0% 0.064 0.241 0.021 0.109
HSPA1L Heat-shock 70-kDa protein 1-like 94.65 43.0% 1.040 0.037 0.494 0.524
Proteins are ordered by mean enrichment (Log2 ratio mBidWT–BirA* vs. venus BirA*). Only proteins enriched in all three repeats are shown. Those highlighted in italic
with an underline have CRAPome scores >20%. VDAC2 is highlighted in bold italic with an underline. Bid (highlighted in bold italic) is the mouse protein used as bait.
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Table 2 Summary of enrichment data in nocodazole-treated HeLa cells, from three independent experiments (R1, R2
and R3) comparing mBidWT–BirA* relative to venus BirA*.
Log2(ratio)
Gene name Description/protein name CRAPome% Sequence
coverage
R1 R2 R3 Mean
BID BH3-interacting domain death agonist (mouse) 1.46 N/A 2.416 2.728 4.072 3.072
RPA1 Replication protein A 70-kDa DNA-binding subunit 20.44 2.1% 0.179 0.228 4.966 1.791
G6PD Glucose-6-phosphate 1 dehydrogenase 5.11 5.2% 0.446 0.003 4.326 1.592
FH Fumarate hydratase isoform 1 (fragment) 5.84 8.0% 0.326 1.219 2.902 1.482
BRAP BRCA1-associated protein 4.62 2.2% 0.462 0.242 3.442 1.382
DDX3X ATP-dependent RNA helicase DDX3X 51.58 15.0% 0.449 0.696 2.668 1.271
MYH14 Myosin 14 32.12 37.0% 1.025 0.099 2.656 1.260
CAPG Macrophage-capping protein 1.22 16.0% 1.056 0.061 2.014 1.044
NCAPG Non-SMC condensin I complex, subunit G 14.36 2.8% 0.822 0.094 2.107 1.007
VDAC2 Voltage-dependent anion channel 2 14.11 35% 0.812 0.914 1.154 0.960
LIMCH1 LIM and calponin homology domain-containing protein 1 (fragment) 5.35 2.4% 0.068 0.189 2.532 0.930
SLC25A31 ADP/ATP translocase 4 42.82 37.0% 0.091 0.288 2.392 0.924
EIF4G1 Eukaryotic translation-initiation factor 4 gamma 1 (fragment) 24.82 19.0% 0.468 0.371 1.804 0.881
ARCN1 Archain 1, isoform CRA_b 22.38 9.0% 0.096 0.208 2.311 0.872
NUP155 Nucleoporin 155 kDa 11.92 5.5% 0.647 0.066 1.793 0.836
PCBP2 Poly(rC)-binding protein 2 (fragment) 45.99 25.0% 0.706 0.299 1.491 0.832
MCCC1 Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial 21.41 15.0% 0.006 0.113 2.367 0.829
HSPA9 Stress-70 protein, mitochondrial (fragment) 74.70 26.0% 1.143 0.040 1.143 0.776
HSPA8 Heat-shock cognate 71 kDa of protein (fragment) 96.35 40.0% 0.198 0.250 1.855 0.768
EIF4A1 Eukaryotic initiation factor 4A-I (fragment) 46.23 44.0% 0.250 0.842 0.852 0.648
DLST Dihydrolipoamide S succinyltransferase (E2 component of 2-oxo-
glutarate complex)
13.87 4.4% 0.138 0.326 1.414 0.626
CHD3 Chromodomain-helicase-DNA-binding protein 3 13.63 2.7% 1.232 0.324 0.146 0.567
HNRNPDL Heterogeneous nuclear ribonucleoprotein D-like 33.82 6.3% 0.511 0.327 0.674 0.504
AP3B1 Adaptor-related protein complex 3 beta- 1 subunit isoform 1
(fragment)
9.98 3.0% 0.352 0.218 0.849 0.473
EPRS Bifunctional glutamate/proline–tRNA ligase 38.20 25.0% 0.668 0.145 0.568 0.460
EPS15L1 Epidermal growth-factor receptor substrate 15-like 1 6.57 15.0% 0.402 0.149 0.830 0.460
CHD5 Chromodomain-helicase-DNA-binding protein 5 14.11 1.3% 0.129 0.095 1.137 0.454
AHNAK2 Protein AHNAK2 4.87 9.5% 0.339 0.290 0.475 0.368
DSP Desmoplakin 30.66 21.0% 0.132 0.363 0.272 0.256
PABPC3 Polyadenylate-binding protein 3 31.63 8.6% 0.121 0.309 0.270 0.233
ABCF3 ATP-binding cassette subfamily F member 3 isoform 1 (fragment) 0.73 5.9% 0.143 0.209 0.111 0.154
HUWE1 HECT, UBA and WWE domain- containing 1 18.00 0.3% 0.182 0.049 0.184 0.139
PDLIM1 PDZ and LIM domain protein 1 7.79 35.0% 0.029 0.185 0.095 0.103
Proteins are ordered by mean enrichment (Log2 ratio mBidWT–BirA* vs. venus BirA*). Only proteins enriched in all three repeats are shown. Those highlighted in italic
with an underline have CRAPome scores >20%. VDAC2 is highlighted in bold italic with an underline. Bid (highlighted in bold italic) is the mouse protein used as bait.
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Alternatively, the structure and/or hydrophobicity of Bcl-
2 proteins might mean that these proteins are undetect-
able by BioID-MS. We therefore asked whether Bcl-2
proteins and/or other STRING-predicted interaction
partners were detected in any of the experimental repli-
cates by lowering selection stringency to include proteins
enriched in one or two repeats (Fig. 2C). Bax was enriched
with mBidWT–BirA* in two repeats, while Bcl-XL was
identified in one. Having shown above that tBid–BirA*
was capable of biotinylating Bcl-XL in cells (Supplemen-
tary Fig. S1C), the inefficient labelling of Bcl-XL and Bax
suggested that these proteins were not predominantly in
close proximity to FL mBid–BirA* in non-apoptotic cells.
As the purpose of the screen was to take an unbiased
approach to FL-Bid’s interactions in mitosis, we restricted
further analysis to those proteins enriched in all three
experimental replicates. Together, these data suggested
that Bcl-2 family proteins may not represent the main
interaction partners for FL-Bid in live cells.
VDAC2 is a potential Bid partner in mitosis
A common issue with AP–MS experiments is detection
of background contaminants. Given the absence of pre-
dicted Bid-interaction partners, we were concerned that
BioID might have predominantly isolated non-specific
proteins. To validate candidates, we first compared the
sequence coverage of each protein and its relative repre-
sentation in the contaminant repository for affinity pur-
ification (CRAPome), which collates proteins commonly
found within negative-control AP–MS datasets (Fig. 3A
and Tables 1 and 2)33. Falling within the criteria of high
sequence coverage and low representation in the CRA-
Pome was the mitochondrial porin, VDAC2. VDAC2 has
been extensively linked to Bcl-2 protein-dependent
apoptosis34–37, despite not being represented within Bid’s
STRING-predicted network. Other potential candidate
proteins included E3 ubiquitin–protein ligase HUWE1
(MULE/ARF-BP1), reported to regulate Mcl-1, and
glucose-6-phosphate dehydrogenase (G6PD), a target of
PLK1 in mitosis38,39.
To gain confidence for which candidates might associ-
ate with Bid in mitosis, we compared their enrichment in
unsynchronised and mitotic cells, and between cells
expressing mBidWT–BirA*, mBidS66A–BirA* or
mBidG94E–BirA* (Fig. 3B). As neither mBidS66A nor
mBidG94E increased priming in colon carcinoma cells20,
we predicted that a specific regulatory partner would not
show enrichment with these baits compared to mBidWT.
Of potential candidates, only VDAC2 was enriched in
mitotic cells expressing the mBidWT–BirA* bait com-
pared to unsynchronised cells. Furthermore, VDAC2
enrichment was significantly lower in mitotic cells
expressing either BidS66A–BirA* or BidG94E–BirA*
compared to mBidWT–BirA*. Neither HUWE1 nor
G6PD showed significant enrichment for specific Bid
variants or with mitosis. HUWE1 showed a slight, but not
significant, enrichment with mBidWT–BirA* (Fig. 3B).
Although we cannot discount either protein being
involved in FL-Bid function, we did not pursue them here
as the evidence did not support a role in mitosis.
The proteins we identified that are commonly found in
control AP–MS datasets showed no specific enrichment
either in mitosis or with any of the mBid variants. For
example, mitochondrial heat-shock protein 70 (HSPA9,
mtHsp70) and the ATP-dependent RNA helicase DDX3X
showed no difference between lines expressing
mBidWT–BirA* or the S66A and G94E variants (Fig. 3C).
Notably, VDAC1, which is approximately tenfold more
abundant than VDAC2 in HeLa cells40, was not enriched
in any sample. Importantly, all quantification was per-
formed using only non-conflicting peptides, so sequence
similarity between VDAC isoforms was not a
confounding issue.
Thus, BioID identified VDAC2 as the principal candi-
date for a Bid phosphorylation-specific role in
mitotic cells.
VDAC2 couples Bid phosphorylation with increased
apoptotic priming in mitosis
As VDAC2 was a potential interaction partner for Bid,
we asked whether it and FL-Bid showed similar spatial
localisation within the cell. To test this, MCF-7 cells stably
expressing mBidWT-GFP were transfected with VDAC2
tagged with a C-terminal V5 epitope (VDAC2-V5). We
used VDAC2-V5 as there were no specific antibodies
suitable for VDAC2. Previous studies have shown that
exogenously expressed VDAC2 with a C-terminal tag is
functional and localises to mitochondria, and we observed
a similar subcellular distribution41 (Supplementary Fig.
S2A). Cells expressing mBidWT-GFP and VDAC2-V5
immunostained for GFP and V5 showed that both co-
localised in a punctate distribution, suggestive of mito-
chondria (Supplementary Fig S2B, C).
As co-localisation does not confirm an interaction
between proteins, we next sought functional validation.
VDAC2 has been linked to both Bax and Bak34,36,37,42, and
either Bax or Bak is required for Taxol-induced apopto-
sis43. To determine if VDAC2 influenced Taxol-
dependent apoptosis, we employed a CRISPR/Cas9-
knockout (ko) strategy in cells that showed Bid phos-
phorylation- dependent priming in mitosis. We initially
compared the human mammary carcinoma cell lines,
MCF-7 and MDA-MB-231, for susceptibility to apoptosis
vs. slippage following treatment with Taxol. Single-cell-
fate profiles were obtained through live imaging of
unsynchronised cells, in the presence or absence of Taxol,
over 65 h, quantifying entry into mitosis, normal division,
apoptosis and slippage (Supplementary Fig. S3). Few
Pedley et al. Cell Death and Disease          (2020) 11:872 Page 7 of 17
Official journal of the Cell Death Differentiation Association
untreated cells underwent apoptosis. However, in Taxol,
MCF-7 cells predominantly underwent apoptosis,
whereas MDA-MB-231 cells were prone to slippage
(Supplementary Fig. S3D), with inter- and intra-line var-
iation consistent with previous studies2,44. We chose
MCF-7 cells for generating a VDAC2 ko as these pre-
dominantly underwent death in mitosis.
To first confirm that Bid phosphorylation set MCF-7
apoptotic priming in mitosis, we stably knocked down
endogenous hBid using a previously verified lentiviral
Fig. 3 BioID identifies the voltage-dependent anion channel 2, VDAC2, as showing Bid phosphorylation-dependent enrichment in mitotic
cells. A Scatterplots comparing mean-fold change for mBidWT–BirA* vs. venus BirA* with sequence coverage (left panel) and abundance in
published negative-control AP–MS datasets (%CRAPome, right panel). VDAC2 is indicated in both plots as having high sequence coverage, and in
low percentage in CRAPome. B Summary of MS analysis showing protein-abundant fold change for VDAC2, the HECT domain-containing E3-
ubiquitin ligase HUWE1 and glucose-6-phosphate dehydrogenase (G6PD). Data represent mean and SD of three independent replicates. Significance
calculated by unpaired t tests, *P < 0.05, **P < 0.01. C Summary of MS analysis from showing protein-abundant fold change for mtHSP70 and DDX3X,
both of which show relatively high scores for their relative frequency in control AP–MS data.
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shRNA (shBid)20. MCF-7 lines were generated expressing
either shBid alone, or with mBidWT-GFP, mBidS66A-
GFP or mBidG94E-GFP (Fig. 4A). We simultaneously
expressed shBid and the mBid-GFP variants, using a
ubiquitin promoter to achieve close-to-endogenous
expression levels (Supplementary Fig. S4A), and FACS
to select similar levels for each line. Immunoblotting for
each variant in unsynchronised and mitotic cells indicated
that mBidWT-GFP and mBidG94E-GFP were phos-
phorylated in mitosis, whereas mBidS66A-GFP was not
(Fig. 4A). Quantitative immunoblotting showed that
endogenous hBid expression was reduced by approxi-
mately 70% (Supplementary Fig. S4A).
Flow cytometry showed that Bid expression, phos-
phorylation or apoptotic function did not affect normal
cell-cycle progression (Fig. 4B). We compared single-cell
fates for parental MCF-7 (WT MCF-7) cells with those
expressing shBid, alone or with each mBid-GFP variant.
In the absence of Taxol, there was no significant apoptosis
or slippage in any of the lines (Fig. 4C, D). However, in the
presence of Taxol, Bid knockdown significantly shifted
MCF-7 cell fate towards slippage (Fig. 4C, D). This was
corrected by expression of mBidWT-GFP, but not by
mBidS66A-GFP or mBidG94E-GFP. Knockdown of hBid
or expression of any of the FL-Bid variants had no impact
on the time untreated cells spent in mitosis (Fig. 4C, E).
Taxol clearly increased the time cells spent in mitosis.
Loss of Bid expression slightly increased the time in
Taxol-arrested mitosis relative to parental cells, which
was accounted for by the increase in time KD cells were
able to remain in mitosis before inducing apoptosis, but
not slippage (Supplementary Fig. S4B). Thus, Bid phos-
phorylation and pro-apoptotic function were required for
increasing priming in MCF-7 cells during mitosis. The
level of Taxol-induced apoptosis in all the shBid MCF-7
lines could be reset to that of WT MCF-7 cells by treating
with the BH3 mimetic, ABT737, indicating that the effect
of Bid phosphorylation was to set the level of mitochon-
drial priming, and suggesting that it was functioning as a
sensitiser (Supplementary Fig. S5A, B). ABT737 in the
absence of Taxol had no effect on apoptosis. MDA-MB-
231 cells stably expressing shBid with mBidWT-GFP,
mBidS66A-GFP or mBidG94E-GFP were also examined
(Supplementary Fig. S5C, D). As with MCF-7 cells, the Bid
variants by themselves did not alter normal mitosis.
Interestingly, although the priming baseline in MDA-MB-
231 was higher than for MCF-7, there was still an
observable reduction in apoptosis in Taxol for cells
expressing BidS66A-GFP or BidG94E-GFP compared
with mBidWT-GFP, although this was not significant.
As MCF-7 cells showed Bid phosphorylation-dependent
priming in mitosis, we targeted the start of the protein-
coding region of the VDAC2 gene in them using CRISPR/
Cas9. Three independent clones containing indels were
identified, termed D11, D6 and D4 (Fig. 5A). MCF-7 cells
have three copies of VDAC2. In the absence of a VDAC2-
specific antibody, we confirmed VDAC2 deletion by
sequencing PCR-amplified regions of the VDAC2 gene.
Sequencing indicated that for D11, all three copies con-
tained frame-shift insertions. D6 had two frame-shift
insertions and one WT allele, and D4 two frame-shift
insertions and one allele with a 3-bp deletion just after the
start of the coding sequence.
We performed cell-fate analysis to compare WT MCF-7
cells to the VDAC2 ko lines (Fig. 5B). There were no
differences in normal mitotic progression in untreated
cells. However, when treated with Taxol, all three VDAC2
ko lines showed a shift towards slippage compared to
WT cells. Furthermore, the proportion of each VDAC2 ko
line undergoing slippage was comparable to that seen
with shBid MCF-7 cells, or those expressing mBidS66A or
mBidG94E (cf. Fig. 4C). Stably expressing VDAC2-V5
(Fig. 5C) in the MCF-7 D11 line restored the level of
apoptosis in Taxol to that of WT MCF-7 cells (Fig. 5D
and Supplementary Fig. S6A). We compared expression of
Bcl-2 family proteins in WT, D11 and D11-VDAC-V5
cells (Supplementary Fig. S6B). As previously shown,
VDAC2 ko reduced Bak expression, which was restored in
D11-VDAC-V5 cells42. There were corresponding
increases in Bax and Puma in the D11 cells, but no change
in expression of Bcl-XL, Mcl-1, Bim or Bid.
We asked if VDAC2 was required for coupling Bid
phosphorylation to priming. The D11 line was stably
transduced with shBid alone, or shBid along with mBidWT-
GFP, mBidS66A-GFP or mBidG94E-GFP (Fig. 5C). Nota-
bly, both mBidWT-GFP and mBidG94E-GFP were still
phosphorylated in mitotic D11 cells, seen with the mobility
shift in the presence of nocadazole. Cell- fate profiling in the
presence or absence of Taxol compared each mBid-GFP
D11 line to WT MCF-7, the D11 ko and D11-VDAC2-V5
cells (Supplementary Fig. S6A). Bid knockdown had no
additive effect on apoptosis beyond that already brought
about by VDAC2 deletion (Fig. 5D). mBidWT-GFP-,
mBidS66A-GFP- or mBidG94E-GFP-expressing D11 cells
all showed the same proportion of death vs. slippage in
Taxol as the D11-VDAC2 ko (Fig. 5D). Importantly,
apoptosis in D11 cells was comparable to shBidMCF-7 cells
(cf. Fig. 4C, D). As in Supplementary Fig. S5A, apoptosis
following Taxol in all lines was restored to the level of WT
MCF-7 cells by treating with ABT737 in combination with
Taxol, indicating that VDAC2 deletion did not simply make
MCF-7 cells incapable of apoptosis via the intrinsic pathway
following delayed mitotic exit. ABT737 by itself did not
induce apoptosis in any of the lines, further indicating that
cell death is a response to the delay in mitotic exit. These
data show that VDAC2 is required to coordinate the
changes in apoptotic priming in response to Bid phos-
phorylation in mitosis.
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Fig. 4 (See legend on next page.)
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Discussion
Cells constantly balance a multitude of pro-survival and
pro-death signals. However, it is still unclear how Bcl-2
proteins dynamically adjust this balance in response to
rapidly changing circumstances. Using an unbiased pro-
teomic approach to label Bid vicinal proteins, we identi-
fied VDAC2 as a coordinator of dynamic apoptotic
priming in mitotic cells. As BioID catalyses protein biotin
labelling in situ, it allows extraction of integral membrane
components without having to maintain direct
protein–protein interactions, thus avoiding issues with
alterations to Bcl-2 protein interactions in detergents28.
Unbiased AP–MS approaches suffer background con-
taminants, and we used a number of approaches to
identify specific interactions. First, by using both
BidS66A–BirA* and BidG94E–BirA*, we identified
VDAC2 as the only candidate specifically enriched in
mitotic cells when Bid was both phosphorylated and had a
functional BH3 domain. Thus, VDAC2 enrichment by FL-
Bid–BirA* showed a specificity for bait proteins that
matched their function in priming mitotic cells. Second,
the three mammalian isoforms of VDAC show high
sequence similarity, but have distinct roles45. Although
VDAC1 is tenfold more abundant than VDAC2 in HeLa
cells40, it was not enriched by any of the mBid–BirA*
variants. Third, functional validation through VDAC2
deletion in a cell line (MCF-7) distinct from that used in
screen, uncoupled mitotic priming from Bid phosphor-
ylation. Bid was still phosphorylated in mitotic VDAC2 ko
cells, indicating that VDAC2 lies downstream of potential
Bid kinases. Loss of VDAC2 dampened priming in mitosis
to the same extent as seen with Bid knockdown, and itsr
combined loss was not additive. Importantly, VDAC2 ko
MCF-7 cells were not simply resistant to apoptosis in
response to mitotic arrest, as cell death following treat-
ment with Taxol was fully restored with the BH3 mimetic
ABT737. Taken together, these data indicate that VDAC2
coordinates FL-Bid functioning as a sensitiser BH3-only
protein in this context.
Previous studies have shown that VDAC2 is required
for tBid-induced apoptosis in mouse embryonic
fibroblasts (MEFs)41,42, through recruitment of Bak to
mitochondria46. Consistent with this, we observed that
VDAC2-deficient MCF-7 cells expressed less Bak,
although there appeared to be a compensatory increase in
Bax. As Bid preferentially activates Bak47, together, these
findings might suggest a phospho-Bid-VDAC2-Bak axis
regulating priming in mitosis. However, the literature on
VDAC2 in Bcl-2 protein function is more complicated
and contradictory. Originally, VDAC2 was found to
inhibit Bak-dependent MOMP, and overexpression of
VDAC2 suppressed Bak activation by tBid34. A more
recent genome-wide CRISPR/Cas9 screen in Mcl-1-
deficient MEFs identified VDAC2 as a mediator of Bax-,
not Bak-dependent apoptosis37. Yet another study found
that Bax retrotranslocation from mitochondria was
mediated by VDAC2, and that it functioned as a platform
to coordinate the interaction between Bax and Bcl-XL36.
Whilst its role in apoptosis remains unclear, our data
support a pivotal role for VDAC2 as a nexus for Bcl-2
protein coordination on the mitochondria, the precise
function being context- and stimulus-specific.
The mechanism by which FL-Bid and VDAC2 coordi-
nate apoptotic priming in mitosis remains to be eluci-
dated. phospho-Bid might displace bound Bak or Bax
from VDAC2, or bind directly to VDAC2- bound Bak or
Bax to trigger activation. However, elucidating the
mechanistic details presents some technical issues. Both
Bak and VDAC2 are integral mitochondrial membrane
proteins, and the denaturing conditions required to
extract them would likely not be compatible with con-
ventional co-immunoprecipitation approaches. To this
end, the use of approaches such as BioID can provide
novel insights.
The lack of canonical Bcl-2 family proteins identified
using FL-Bid as our bait was unexpected. Bid was ori-
ginally identified as an interacting partner of both Bcl-2
and Bax using a phage-expression library48. Whilst FL-Bid
is pro-apoptotic49,50, it has been predominantly studied in
the context of cleavage by caspase 8, which converts Bid
into a potent direct activator BH3-only protein51,52. Thus,
interacting partners of Bid defined in the literature and
(see figure on previous page)
Fig. 4 Phosphorylation of Bid regulates apoptotic priming in mitotic breast-cancer cells. A MCF-7 cell lines were generated stably expressing
either shBid alone or with the indicated mouse Bid-GFP variant (mBidWT-GFP, mBidS66A-GFP and mBidG94E-GFP). Cells were either untreated (−) or
enriched for mitosis with 18-h treatment in nocodazole followed by shake off (+). Whole-cell lysates were immunoblotted with the indicated
antibodies. Anti-vinculin serves as loading control, while anti-phospho-histone H3 (pH 3) indicates mitosis. B Cell-cycle distribution for the MCF-7
lines in A, quantified through DAPI staining and flow cytometry. Data were obtained using unsynchronised cells. Data represent mean and SD of 2
independent repeats. C Single-cell-fate profiles of the MCF-7 lines in A, untreated control or treated with 1 μM Taxol over 50 h. Data represent 90 cells
tracked over three independent experiments. D Summary of apoptosis in mitosis for the data in C for the indicated MCF-7 cell lines. Mean and SD are
shown. Data were analysed by one-way ANOVA, followed by Tukey’s multiple-comparison test (ns= non-significant; ***P < 0.001; ****P < 0.0001). E
Summary of the duration of mitosis, all fates included, for the data in C. Mean and SD plotted. Data analysed by one-way ANOVA, followed by Tukey’s
multiple- comparison test (ns= non-significant; ***P < 0.001; ****P < 0.0001).
Pedley et al. Cell Death and Disease          (2020) 11:872 Page 11 of 17
Official journal of the Cell Death Differentiation Association
represented in STRING are those associated with its
cleaved form in dead or dying cells. tBid–BirA*-labelled
GFP-Bcl-XL, and Bcl-XL and Bax peptides were detected
in our BioID screen in some experimental replicates.
However, these interactions may represent those cells that
have committed to apoptosis, whereas in cells that have
not yet committed, FL-Bid may associate with proteins
outside the Bcl-2 family and extrinsic pathway. Other
Fig. 5 Voltage-dependent anion channel 2 (VDAC2) coordinates Bid phosphorylation-dependent apoptotic priming in mitosis. A Single
MCF-7 cell clones were grown following CRISPR/Cas9 targeting of VDAC2. Left-hand panel—agarose gel electrophoresis of 300-bp PCR product at
VDAC2 CRISPR target PAM site. Right-hand panel—table displaying indels caused by CRISPR/Cas9 determined by direct DNA sequencing of the
amplified regions. B Single-cell-fate profiles of the three MCF-7 VDAC2 KO lines in A, untreated (control) or treated with 1 μM Taxol over 48 h. Data
represent 90 cells over three independent experiments. Percentage of death in mitosis is shown for Taxol-treated cells. C D11 VDAC2 KO MCF-7 cell
lines were generated stably expressing VDAC2-V5, shBid alone or shBid in conjunction with the indicated full-length mouse Bid-GFP variants
(mBidWT-GFP, mBidS66A-GFP and mBidG94E-GFP). Cells were either untreated or enriched for mitosis with 18-h treatment in nocodazole followed
by shake off. Whole-cell lysates were immunoblotted with the indicated antibodies. β-actin serves as loading control, while phospho-histone H3 (pH
3) indicates mitosis. D Summary of apoptosis in mitosis for single-cell-fate analysis of the cell lines in C, untreated or treated with 1 μM Taxol and/or
5 μM ABT737 over 48 h (single-cell traces in Supplementary Fig. S5C). Data represent 90 cells tracked over three independent experiments. Error bars
represent SD. Data analysed by one-way ANOVA, followed by Tukey’s multiple-comparison test. ns = non-significant, **P < 0.01, ***P < 0.001.
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non-canonical interactions have been identified for BH3-
only proteins53,54, and using an approach such as BioID
will allow interrogation of the Bcl-2 family interactome in
a non-apoptotic context. With the advent of Bcl-2 pro-
tein-targeted drugs, it is essential to understand the wider
interactions of these proteins and the complex layers of
regulation, which modulate their function.
Finally, these results add to our understanding of how
cells coordinate the dynamic changes in priming during
mitosis. Mitosis represents a clinically important ther-
apeutic target for drugs like Taxol, and numerous studies
have implicated roles for different Bcl-2 family proteins. A
genome-wide screen in HeLa cells identified Bax as a key
protein for Taxol-mediated cell death, whereas the same
approach in colon carcinoma cells did not directly identify
any Bcl-2 protein, but instead found a Myc-dependent
transcription of Bid, Bim and Noxa21,22. An siRNA
approach in HeLa cells specifically targeted at Bcl-2 pro-
teins identified roles for Noxa, Bim and Mcl-155. Together,
these studies indicate that the outcome of delayed mitotic
exit is not determined by a single BH3 protein or multi-
domain effector, but rather the dynamic interplay of many,
the balance of which varies between, and likely within, cell
types. Several Bcl-2 proteins undergo mitosis-specific
modifications, including Bcl-2, Bcl-XL, Mcl-1, Bid and
BimEL, each appearing to have distinct roles17–20. However,
collectively, they result in the dynamic accumulation of
apoptotic priming if anaphase is delayed9. Our data now
show that, unlike caspase-8 cleavage, phosphorylation of
FL-Bid does not convert it into an activator BH3-only
protein. Instead, phosphorylated FL-Bid reversibly increases
apoptotic priming in mitosis (Fig. 6). It is interesting to
speculate that in addition to its established function as a
direct activator downstream of death receptors, a significant
role for Bid may be as a sensitiser during the cell cycle.
Methods
Cell culture
MCF-7, BT-474, MDA-MB-231, SK-BR-3, MCF-10A,
HEK-293T and HeLa cells were acquired from ATCC
(American Type Culture Collection). MCF-10A cells were
grown in DMEM-F12 supplemented with 5% horse serum
(v/v), 100 ng/ml cholera toxin, 20 ng/ml epidermal growth
factor, 0.5 g/ml hydrocortisone, 10 mg/ml insulin, 100
U/ml penicillin and 100mg/ml streptomycin. HeLa cells
were grown in EMEM supplemented with 10% foetal
bovine serum (v/v), 100 U/ml penicillin and 100mg/ml
streptomycin. All other cell lines were cultured in DMEM
supplemented with 10% foetal bovine serum (v/v), 100
U/ml penicillin and 100mg/ml streptomycin.
Single-cell-fate tracking
In all, 1 µM Taxol (Sigma-Aldrich), 5 µM ABT737
(Sigma-Aldrich) or DMSO diluted in complete growth
media was added to cells 30 min prior to imaging. Images
were acquired at 15-min intervals for 48–60 h on an AS
MDW live-cell imaging system (Leica) in bright field
using a ×20 objective and utilising imaging software
Image Pro 6.3 (Media Cybernetics Ltd). Point visiting was
used to allow multiple positions to be imaged within the
same time course, and cells were maintained at 37 °C and
5% CO2. Image stacks were analysed in ImageJ (National
Institutes of Health), where single cells were identified
and followed manually using cellular morphology to
determine cell-cycle progression and fate. Cells were
described as being in mitosis from the initial point at
which a cell began to round, until the first frame of
cytokinesis or membrane blebbing. Cells that exhibited
morphology associated with apoptosis, such as membrane
blebbing, shrinking of the cell body, and in the later
stages, the formation of apoptotic bodies or secondary
necrosis was described as having undergone apoptosis in
mitosis. Cells that exited mitosis as a single cell, or as two
or more non-identical daughter cells, were grouped
together under the definition of having undergone mitotic
slippage.
Antibodies, immunofluorescence and immunoblotting
The following antibodies were used for immunoblotting
and immunoflourescence: rabbit anti-Bid (ProteinTech, #
10988-1-AP), mouse anti-Myc (Millipore, # 05-724),
rabbit anti-V5 (Sigma-Aldrich, # V8157), mouse anti-
mtHsp70 (Thermo, # MA3-028), rabbit anti-GFP (Invi-
trogen, # PA1-9533), goat anti-β-actin (Abcam, #
Ab8229), rabbit anti-phospho-Histone serine10 (Milli-
pore, # 06-570) and mouse anti-vinculin (Abcam, #
Ab9532). To detect biotinylated proteins, we used
DyLight 549 Streptavidin (Vector laboratories, # SA-5549)
and IRDye680 Strepavidin (LiCor, # 925-68079).
Immunofluorescent staining of cells was performed as
previously described6, using Alexafluor 594- and 488-
conjugated secondary antibodies (Stratech). Immunos-
tained cells were visualised (wide field) using a Zeiss
AxioImager M2 florescence microscope with ×63 (NA
1.4) PLAN-APOCHROMAT objective. Images were
acquired with Micro-Manager software and processed
using ImageJ. For confocal microscopy, images were
collected on a Leica TCS SP8 AOBS-inverted confocal
using a ×20 Plan Fluotar objective and ×3 confocal
zoom. The confocal settings were as follows: pinhole 0.6
airy unit, scan speed 1000-Hz unidirectional. Images
were collected sequentially to eliminate crosstalk
between channels. When acquiring 3D optical stacks,
the confocal software was used to determine the optimal
number of Z sections. Raw images were then decon-
volved using the Huygens Pro software (SVI), and
maximum-intensity projections of these deconvolved
images are shown in the ‘Results’.
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For immunoblotting, proteins were separated by SDS
PAGE and transferred to nitrocellulose. Following incu-
bation with primary antibodies, proteins were detected
using IrDye 800 and 680 secondary antibodies and an
Odyssey CLx imager (LiCor). Quantification of blots was
performed using ImageStudio (LiCor).
Mitotic enrichment of cultured cells
Asynchronous cell populations were treated with
nocodazole (Sigma-Aldrich, 200 ng/mL in complete
growth media) for 16 h to arrest cells in mitosis. Mitotic
cells were then dislodged from the cell-culture dish by
tapping the vessel laterally against the bench. Media
containing dislodged mitotic cells was removed and cen-
trifuged at 350 RCF for 5 min to pellet cells ready for
subsequent analysis.
Flow-cytometry analysis of the cell cycle
Cell-cycle distribution within a population was quanti-
fied by DNA content. Cycling cells were fixed with 70%
ethanol and stained with DAPI. Stained cell samples were
analysed on a BD Biosciences Fortessa flow cytometer,
using Diva Version 8 (BD Biosciences) to collect raw data.
Raw data were then analysed using Modfit LT (Version 5,
Verity Software House) to quantify the distribution
between cell-cycle phases.
BioID-mediated proximity labelling
For small-scale assays such as western blotting or
immunofluorescent staining, cells expressing BirA*-fusion
proteins were seeded into a 6-well plate to ~80% con-
fluence on the day of labelling. Growth media was
replaced with complete growth media supplemented with
50 µM biotin (Sigma-Aldrich), and cells cultured for a
further 16 h. Following incubation, biotin-supplemented
media was removed and replaced with regular growth
media for 1 h. Cells were then washed three times in PBS
and assayed as appropriate.
For mass-spectrometry experiments, cells expressing
BioID-fusion proteins were seeded into two 100-mm-
diameter dishes to be approximately 80% confluent the
next day. On the day of labelling, growth media was
replaced with complete growth media supplemented with
50 µM biotin (Sigma-Aldrich) and cultured for a further
16 h, along with any other drug treatment. Following
incubation, biotin-supplemented media was removed and
replaced with regular growth media for 1 h to allow free
biotin to diffuse out of cells. Cells were then washed three
times in PBS and lysed in RIPA supplemented with 1×
protease inhibitor cocktail (Millipore), 100 mM Na3VO4
and 500mM NaF. Following lysis, lysates from both
dishes were pooled, protein concentration measured and
biotinylated proteins isolated via streptavidin-bead
purification.
Streptavidin-affinity purification
Biotinylated proteins were isolated using MagReSyn®
streptavidin (MagReSyn®). In total, 100 µL of bead slurry
was decanted into a microcentrifuge tube and exposed to
a magnetic field to separate the liquid and bead phases.
The liquid phase was discarded, and beads were washed
three times in ice-cold lysis buffer. Appropriate volumes
of cell lysate were added to beads to yield 1 mg of total
protein, and the volume made up to a total of 1 mL with
lysis buffer. Lysates and beads were incubated overnight at
4 °C on an end-over-end tumbler. The next day, beads
were collected, washed twice in lysis buffer, once in urea
wash buffer (2M urea, 10 mM Tris-HCl, pH 8.0), then
three more times with lysis buffer. Following the final
wash, beads were resuspended in 100 µL of 1× lithium
dodecyl sulfate sample buffer (Novex NuPAGE) supple-
mented with 2 mM biotin and 50mM dithiothreitol
(DTT) and incubated at 95 °C for 5 min to elute bound
proteins. Following elution, beads were collected and
concentrated to 50 µL in a vacuum concentrator. In all,
45 µL of sample was immediately subjected to SDS PAGE
and processed for digestion in preparation for mass
spectrometry, while the remaining 5 µL was analysed via
western blotting to confirm biotinylation and protein
enrichment.
Mass spectrometry and protein identification
Affinity-purified biotinylated protein samples were
briefly separated by SDS PAGE, then fixed and stained
using InstantBlue (Expedeon). Gel fragments containing
protein samples were digested with trypsin and peptides
extracted under standard conditions. Peptides were sub-
jected to liquid chromatography tandem mass spectro-
metry (LC–MS/MS) using a Thermo Orbitrap Elite
coupled with a Thermo nanoRSLC system (Thermo
Fisher Scientific). Peptides were selected for fragmenta-
tion automatically by data-dependent analysis. Raw data
were processed using Progenesis QI (v4.1, Nonlinear
Dynamics) and searched against the SwissProt and
Trembl databases (accessed July, 2017). Database searches
were performed against the human, mouse and E. coli
proteome databases with tryptic digest specificity, allow-
ing a maximum of two missed cleavages, and an initial
mass tolerance of 5 ppm (parts per million). Carbami-
domethylation of cysteine was applied as a fixed mod-
ification, while N-acylation and oxidation of methionine,
as well as the biotinylation of lysine, were applied as
variable modifications during the database searches.
Label-free protein quantification and data analysis
Relative label-free protein quantification of mass-
spectrometry experiments was performed using Progen-
esis QI (v4.1, Nonlinear Dynamics). Raw data were pro-
cessed and aligned in Progenesis QI. Once aligned,
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relative protein quantification was calculated from the
abundances of ions with three or more isoforms identified
as being from unique (non-conflicting) peptides. Com-
parisons between relative protein abundances were made
between proteins isolated from wild-type or mutant
Bid–BirA* lysates (sample) and proteins isolated from
venus-BirA* lysates (control) to calculate a fold change.
Sample and control protein abundances were paired
based on drug treatment, e.g., WTBid-BirA*+ nocoda-
zole was compared with venus BirA*+ nocodazole. Sta-
tistical analysis of proteomics data was performed in
Progenesis QI using ANOVA.
STRING analysis
Predicted interaction networks were computed by
STRING (Search Tool for the Retrieval of Interacting
Genes/Proteins) from the top 10 highest-scoring pre-
dicted functional partners for Bid31,32. Only data from
experimental validated interactions and interactions in
curated databases were used to score predicted functional
partners. STRING Database v11.0, accessed April 2019.
VDAC2 deletion by CRISPR/Cas9
Deletion of endogenous VDAC2 was achieved through
CRISPR/Cas9. Two sgRNA sequences (CAATGTG-
TATTCCTCCATC, GATGGAGGAATACACATTG),
designed to target upstream of the second protein-coding
exon, were cloned into PX458 (pSpCas9(BB)-2A-GFP).
PX458 containing the VDAC2-targeting guides was
transfected into low-passage WT MCF-7 cells and sorted
by FACS for GFP expression. Single cells were isolated
from the sort and plated into individual wells of 96-well
plates. Wells in which clonal cell populations had
expanded were transferred to larger cultures, and geno-
mic DNA extracted for identification of indels by PCR and
sequencing.
Statistical analysis
Statistical analysis was performed using GraphPad
Prism v7. Details of specific tests used, the number of
biological replicates and sample size, are given in the
figure legends.
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